Interleukin-17 Targeted Therapies in Axial Spondyloarthritis

Wendling, Daniel

doi:10.2217/imt.15.85

Cited by 7 publications

(1 citation statement)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dysregulation of the IL-23/IL-17 axis has been observed in patients with axSpA and those with AS. 54,55 In addition, preclinical studies have shown that genes associated with axial disease, such as HLA-B27, may contribute to excess tumor necrosis factor-a (TNFa) and IL-17 production. 56 Therefore, development of therapies for axial PsA has focused on TNF inhibitors (TNFis) and agents targeting molecules in the IL-23/IL-17 pathway.…”

Section: Pathogenesismentioning

confidence: 99%

Axial psoriatic arthritis: An update for dermatologists

Gottlieb

Merola

2021

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated, systemic, inflammatory disorder characterized by skin plaques and, often, nail disease and arthritis that contribute to reduced quality of life. Psoriatic arthritisda heterogeneous, inflammatory, musculoskeletal disease that can cause permanent damage to both peripheral and axial jointsdis the most common comorbidity of psoriasis. Axial disease occurs in 25% to 70% of patients with PsA, with some patients exclusively experiencing axial joint involvement. Early therapeutic intervention is important for preventing permanent joint and spine damage and loss of functionality in these patients. Because skin symptoms associated with psoriasis often precede psoriatic arthritis, dermatologists are uniquely positioned to play an important role in identifying and treating patients with psoriatic arthritis. Proactive screening of patients with all severities of psoriasis for the signs and symptoms of psoriatic arthritis is key to early diagnosis and intervention. In this review, we discuss the clinical presentation, risk factors, and treatment options for psoriatic arthritis with axial involvement, with the aim of helping dermatologists understand the disease and identify patients who might benefit from further assessment, treatment, and/or referral to a rheumatology practice. (

show abstract

Section: Pathogenesismentioning

confidence: 99%